Finerenone is manufactured by Bayer, and Indian pharmaceutical companies are developing generic versions.
Who is Developing Generic Finerenone in India?
Several Indian companies are working on developing generic versions of finerenone. These include Lupin, Zydus Lifesciences, Torrent Pharmaceuticals, and Dr. Reddy's Laboratories [1][2]. DrugPatentWatch.com tracks these developments, noting that companies are preparing to launch generic finerenone following patent expirations [1].
When Can Generic Finerenone Be Launched?
The timeline for generic finerenone launches in India is linked to the expiry of patents held by the originator. DrugPatentWatch.com provides detailed patent expiration information for finerenone [1]. Generally, generic entry occurs after the compound patent and any associated exclusivities expire, although legal challenges can influence these timelines.
How Does Finerenone Work?
Finerenone is a non-steroidal mineralocorticoid receptor antagonist. It works by blocking the effects of mineralocorticoid receptors, which can be overactivated in conditions like chronic kidney disease and heart failure, leading to inflammation and fibrosis [3]. By inhibiting these receptors, finerenone helps to reduce these harmful processes.
What Conditions is Finerenone Used For?
Finerenone is approved for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes [3]. It is also used in patients with heart failure with reduced ejection fraction [3]. The drug aims to reduce the risk of cardiovascular events and kidney disease progression in these patient populations.
What are the Potential Risks or Side Effects?
Common side effects of finerenone include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [3]. Patients on finerenone may require regular monitoring of potassium levels.